Every extra pound of body weight puts approximately 4 pounds of pressure on the knee joints. For someone 50 pounds overweight, that's 200 additional pounds of force on every step. It's no surprise that weight loss is the most recommended intervention for knee osteoarthritis — but until recently, achieving sufficient weight loss through diet and exercise alone was exceedingly difficult for most patients.
GLP-1 medications have changed that math entirely.
The Clinical Evidence
In December 2025, Eli Lilly reported results from a retatrutide trial specifically enrolling patients with knee osteoarthritis. The findings were striking:
- Participants lost an average of up to 29% of their body weight (approximately 71 pounds)
- Knee pain decreased significantly compared to placebo
- Physical function improved measurably
This wasn't a study designed to measure weight loss that happened to notice joint improvement — it was specifically designed to evaluate the impact on osteoarthritis outcomes. That represents a meaningful evolution in how GLP-1 medications are being studied and potentially used.
Why Weight Loss Helps Joints So Much
The 4:1 force multiplier means the benefits of weight loss for knee health are dramatic:
- Losing 10 pounds removes approximately 40 pounds of pressure from the knees per step
- Losing 30 pounds removes approximately 120 pounds of pressure per step
- Losing 50+ pounds (common with GLP-1 medications) can transform joint function entirely
Beyond the mechanical load reduction, weight loss also decreases systemic inflammation — a key driver of osteoarthritis progression. GLP-1 medications appear to have anti-inflammatory properties independent of weight loss, though the research on this is still developing.
The Exercise Paradox
Doctors routinely tell osteoarthritis patients to lose weight and exercise more. But severe knee pain makes exercise agonizing. GLP-1 medications break this cycle: significant weight loss without high-impact exercise, which then makes exercise more comfortable, which accelerates further improvement. It's a positive feedback loop that was previously very hard to initiate.
Currently Available Options
While retatrutide is still in clinical trials (expected availability 2027–2028), today's GLP-1 medications already produce meaningful weight loss for joint health:
- Tirzepatide (Zepbound) — 20–22% average weight loss, equivalent to 40–55 lbs for many patients. This level of weight loss removes 160–220 lbs of knee pressure per step.
- Semaglutide (Wegovy) — 15–17% average weight loss, equivalent to 30–42 lbs. Still removes 120–170 lbs of knee pressure.
For patients whose primary motivation for weight loss is joint pain rather than (or in addition to) metabolic health, the treatment rationale is equally strong.
Care Bare Rx
Physician-guided GLP-1 treatment with comprehensive care. Care Bare offers both semaglutide and tirzepatide options with fast onboarding.
Get Started →Talking to Your Doctor
If knee pain is a significant part of your health picture, mention it when discussing GLP-1 medication with your provider. Osteoarthritis is a weight-related health condition that may help you qualify for treatment even if your BMI is in the 27–30 range (where a comorbidity is required for eligibility).
The conversation isn't just about looking different — it's about moving differently. Reduced pain, improved mobility, and the ability to be physically active again are among the most meaningful quality-of-life improvements that weight loss can deliver.
Oak Weight Loss
Straightforward pricing with no dose escalation costs. Oak provides both injectable and oral GLP-1 options for sustainable weight management.
Get Started →